Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.39 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777442 | 0.87 | PPARG (0.41) | PPARGPPARACTSSCTSKACE | |
| SCHEMBL21777268 | 0.86 | PPARG (0.48) | PPARGPPARACTSSCTSKCNR2 | |
| SCHEMBL8615645 | 0.83 | CTSS (0.46) | PPARGPPARACTSSCTSKACE | |
| SCHEMBL17395943 | 0.82 | CTSS (0.49) | PPARGPPARACTSSCTSKACE | |
| SCHEMBL21777294 | 0.82 | CTSS (0.49) | PPARGPPARACTSSCTSKACE | |
| SCHEMBL265969 | 0.82 | CTSS (0.49) | PPARGPPARACTSSCTSKACE | |
| SCHEMBL21777440 | 0.79 | PPARG (0.42) | PPARGPPARACTSSCTSK | |
| SCHEMBL21777275 | 0.76 | TSHR (0.40) | PPARGPPARACTSSCTSKPTPN1 | |
| SCHEMBL15226488 | 0.76 | CTSS (0.45) | PPARGPPARACTSSCTSKACE | |
| SCHEMBL8619927 | 0.73 | PPARG (0.44) | PPARGPPARACTSSCTSKACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582644-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-24 | — | — | US | disclosed |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2020047251-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047251-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582644-B2 | O-GlcNAc transferase inhibitors and uses thereof | OGA, OGT, OSTC | PPARG 2580/4885PPARA 4249/4885CTSS 1495/4885 |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGT, OGA, UGGT1 | PPARG 2875/4885PPARA 4232/4885CTSS 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.